Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL von Goy, Andre, Ramchandren, Radhakrishnan, Ghosh, Nilanjan, Munoz, Javier, Morgan, David S., Dang, Nam H., Knapp, Mark, Delioukina, Maria, Kingsley, Edwin, Ping, Jerry, Beaupre, Darrin M., Neuenburg, Jutta K., Ruan, Jia

Volltext

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma von Noy, Ariela, de Vos, Sven, Thieblemont, Catherine, Martin, Peter, Flowers, Christopher R., Morschhauser, Franck, Collins, Graham P., Ma, Shuo, Coleman, Morton, Peles, Shachar, Smith, Stephen, Barrientos, Jacqueline C., Smith, Alina, Munneke, Brian, Dimery, Isaiah, Beaupre, Darrin M., Chen, Robert

Volltext

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma von Wilson, Wyndham H, Young, Ryan M, Schmitz, Roland, Yang, Yandan, Pittaluga, Stefania, Wright, George, Lih, Chih-Jian, Williams, P Mickey, Shaffer, Arthur L, Gerecitano, John, de Vos, Sven, Goy, Andre, Kenkre, Vaishalee P, Barr, Paul M, Blum, Kristie A, Shustov, Andrei, Advani, Ranjana, Fowler, Nathan H, Vose, Julie M, Elstrom, Rebecca L, Habermann, Thomas M, Barrientos, Jacqueline C, McGreivy, Jesse, Fardis, Maria, Chang, Betty Y, Clow, Fong, Munneke, Brian, Moussa, Davina, Beaupre, Darrin M, Staudt, Louis M

Volltext

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results von Wang, Michael L., Blum, Kristie A., Martin, Peter, Goy, Andre, Auer, Rebecca, Kahl, Brad S., Jurczak, Wojciech, Advani, Ranjana H., Romaguera, Jorge E., Williams, Michael E., Barrientos, Jacqueline C., Chmielowska, Ewa, Radford, John, Stilgenbauer, Stephan, Dreyling, Martin, Jedrzejczak, Wieslaw Wiktor, Johnson, Peter, Spurgeon, Stephen E., Zhang, Liang, Baher, Linda, Cheng, Mei, Lee, Dana, Beaupre, Darrin M., Rule, Simon

Volltext

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma von Wang, Michael L, Rule, Simon, Martin, Peter, Goy, Andre, Auer, Rebecca, Kahl, Brad S, Jurczak, Wojciech, Advani, Ranjana H, Romaguera, Jorge E, Williams, Michael E, Barrientos, Jacqueline C, Chmielowska, Ewa, Radford, John, Stilgenbauer, Stephan, Dreyling, Martin, Jedrzejczak, Wieslaw Wiktor, Johnson, Peter, Spurgeon, Stephen E, Li, Lei, Zhang, Liang, Newberry, Kate, Ou, Zhishuo, Cheng, Nancy, Fang, Bingliang, McGreivy, Jesse, Clow, Fong, Buggy, Joseph J, Chang, Betty Y, Beaupre, Darrin M, Kunkel, Lori A, Blum, Kristie A

Volltext

Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia von Wang, Eric, Pineda, Jose Mario Bello, Kim, Won Jun, Chen, Sisi, Bourcier, Jessie, Stahl, Maximilian, Hogg, Simon J., Bewersdorf, Jan Phillipp, Han, Cuijuan, Singer, Michael E., Cui, Daniel, Erickson, Caroline E., Tittley, Steven M., Penson, Alexander V., Knorr, Katherine, Stanley, Robert F., Rahman, Jahan, Krishnamoorthy, Gnana, Fagin, James A., Creger, Emily, McMillan, Elizabeth, Mak, Chi-Ching, Jarvis, Matthew, Bossard, Carine, Beaupre, Darrin M., Bradley, Robert K., Abdel-Wahab, Omar

Volltext

Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma von Kuo, Hsu-Ping, Ezell, Scott A, Schweighofer, Karl J, Cheung, Leo W K, Hsieh, Sidney, Apatira, Mutiah, Sirisawad, Mint, Eckert, Karl, Hsu, Ssucheng J, Chen, Chun-Te, Beaupre, Darrin M, Versele, Matthias, Chang, Betty Y

Volltext

Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: learnings from a survey of FDA-approved drugs von Mittapalli, Rajendar K., Yin, Donghua, Beaupre, Darrin, Palaparthy, Rameshraja

Volltext

Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advan... von Gordon, Michael S, Sweeney, Christopher S, Mendelson, David S, Eckhardt, S Gail, Anderson, Abraham, Beaupre, Darrin M, Branstetter, Daniel, Burgess, Teresa L, Coxon, Angela, Deng, Hongjie, Kaplan-Lefko, Paula, Leitch, Ian M, Oliner, Kelly S, Yan, Lucy, Zhu, Min, Gore, Lia

Volltext

The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma von Fowler, Nathan H., Nastoupil, Loretta, De Vos, Sven, Knapp, Mark, Flinn, Ian W., Chen, Robert, Advani, Ranjana H., Bhatia, Sumeet, Martin, Peter, Mena, Raul, Davis, Richard Eric, Neelapu, Sattva S., Eckert, Karl, Ping, Jerry, Co, Melannie, Beaupre, Darrin M., Neuenburg, Jutta K., Palomba, M. Lia

Volltext

Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development von Yap, Timothy A, Jacobs, Ira, Baumfeld Andre, Elodie, Lee, Lauren J, Beaupre, Darrin, Azoulay, Laurent

Volltext

Ibrutinib‐associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma von Furtado, Michelle, Wang, Michael L., Munneke, Brian, McGreivy, Jesse, Beaupre, Darrin M., Rule, Simon

Volltext

Tipifarnib-Induced Apoptosis in Acute Myeloid Leukemia and Multiple Myeloma Cells Depends on Ca2+ Influx through Plasma Membrane Ca2+ Channels von Yanamandra, Niranjan, Buzzeo, Robert W., Gabriel, Mark, Hazlehurst, Lori A., Mari, Yelenis, Beaupre, Darrin M., Cuevas, Javier

Volltext

A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced Solid Tumors von ROSEN, Peter J, SWEENEY, Christopher J, YEE, Lorrin K, PARK, Dorothy J, BEAUPRE, Darrin M, HONGJIE DENG, LEITCH, Ian M, SHUBHAKAR, Poornima, MIN ZHU, OLINER, Kelly S, ANDERSON, Abraham

Volltext

Tipifarnib and Bortezomib Are Synergistic and Overcome Cell Adhesion–Mediated Drug Resistance in Multiple Myeloma and Acute Myeloid Leukemia von YANAMANDRA, Niranjan, COLACO, Nandita M, PARQUET, Nancy A, BUZZER, Robert W, BOULWARE, David, WRIGHT, Gabriela, PEREZ, Lia E, DALTON, William S, BEAUPRE, Darrin M

Volltext

A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors von Hong, David S, Rosen, Peter, Lockhart, A Craig, Fu, Siqing, Janku, Filip, Kurzrock, Razelle, Khan, Rabia, Amore, Benny, Caudillo, Isaac, Deng, Hongjie, Hwang, Yuying C, Loberg, Robert, Ngarmchamnanrith, Gataree, Beaupre, Darrin M, Lee, Peter

Volltext

Characterization of a R115777-Resistant Human Multiple Myeloma Cell Line with Cross-Resistance to PS-341 von BUZZEO, Robert, ENKEMANN, Steven, NIMMANAPALLI, Rama, ALSINA, Melissa, LICHTENHELD, Mathias G, DALTON, William S, BEAUPRE, Darrin M

Volltext

RAS and Leukemia: From Basic Mechanisms to Gene-Directed Therapy von BEAUPRE, D. M, KURZROCK, R

Volltext

Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open‐label studies von Rule, Simon, Dreyling, Martin, Goy, Andre, Hess, Georg, Auer, Rebecca, Kahl, Brad, Cavazos, Nora, Liu, Black, Yang, Shiyi, Clow, Fong, Goldberg, Jenna D., Beaupre, Darrin, Vermeulen, Jessica, Wildgust, Mark, Wang, Michael

Volltext

Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: Learnings from a survey of approved drugs von Mittapalli, Rajendar K, Yin, Donghua, Beaupre, Darrin M., Palaparthy, Rameshraja

Volltext